NASDAQ: ATTOAttovia Therapeutics Inc Stock
$16.64+0.68 (+4.26%)
Updated Nov 10, 2026
ATTO Price
$16.64
Fair Value Price
$0.41
Market Cap
$760.66M
52 Week Low
$12.98
52 Week High
$28.00
P/E
N/A
P/B
1.91x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.04
Operating Cash Flow
N/A
Beta
1.39
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ATTO Overview
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ATTO's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ATTO
Ranked#338 of 450
Ranked#338 of 450
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $15.83 | A | |
| $916.06 | A | |
| $424.00 | A |
Be the first to know about important ATTO news, forecast changes, insider trades & much more!
ATTO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ATTO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ATTO ($16.64) is overvalued by 3,985.45% relative to our estimate of its Fair Value price of $0.41 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ATTO ($16.64) is not significantly undervalued (3,985.45%) relative to our estimate of its Fair Value price of $0.41 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ATTO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more ATTO due diligence checks available for Premium users.
Valuation
ATTO fair value
Fair Value of ATTO stock based on Discounted Cash Flow (DCF)
Price
$16.64
Fair Value
$0.41
Overvalued by
3,985.45%
ATTO ($16.64) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ATTO ($16.64) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ATTO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.91x
Industry
5.28x
ATTO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ATTO's financial health
Profit margin
Revenue
$0.0
Net Income
-$22.7M
Profit Margin
0%
Assets to liabilities
Assets
$411.8M
Liabilities
$14.1M
Debt to equity
0.04
ATTO's short-term assets ($404.52M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATTO's short-term assets ($404.52M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATTO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$25.7M
Investing
-$199.8M
Financing
$308.0M
ATTO vs Biotech Stocks
Attovia Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.